Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus

GlobeNewswire March 23, 2015

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2014

GlobeNewswire March 20, 2015

Hemispherx Enters a Collaboration with Emerge Health for the Commercialization of Ampligen for Chronic Fatigue Syndrome (CFS) in Australia and New Zealand

GlobeNewswire March 9, 2015

Hemispherx Biopharma Announces the Completion of the Newly Upgraded Alferon(R) Facility: Commercial Production of Alferon(R) is in the Final Stage Integrating Continuous Flow Manufacturing Technology

GlobeNewswire March 2, 2015

Hemispherx Biopharma: Institute of Medicine, the Health Arm of the US National Academy of Sciences Reframes Chronic Fatigue Syndrome (CFS) as a "Systemic Exertion Intolerance Disease" (SEID)

GlobeNewswire February 23, 2015

Hemispherx Biopharma and USAMRIID to Present New Discoveries Concerning the Efficacy of Ampligen(R) Against the Ebola Virus at Upcoming International Symposium on Filoviruses

GlobeNewswire February 12, 2015

Hemispherx Biopharma Posts USAMRIID Ebola Study Concluding Ampligen(R) Produced 100% Survival Rate in Rodents With 100% Mortality in Placebo

GlobeNewswire February 9, 2015

Hemispherx: U.S. Army Scientists (USAMRIID) Find Ampligen(R) Produces 100% Survival Rate in Ebola Virus Rodent Study

GlobeNewswire February 2, 2015

USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments

GlobeNewswire January 26, 2015

Hemispherx Biopharma Awarded $770,852 by Federal Judge

GlobeNewswire January 15, 2015

Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum

GlobeNewswire January 12, 2015

Arrowhead Issues Diligence and Valuation Report on Hemispherx Biopharma

GlobeNewswire January 9, 2015

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors

GlobeNewswire December 16, 2014

Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research

GlobeNewswire December 9, 2014

Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which is Linked to High Mortality in Man

GlobeNewswire November 17, 2014

Hemispherx Biopharma Reports on Annual Stockholder Meeting

GlobeNewswire November 14, 2014

Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2014

GlobeNewswire November 10, 2014

Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon(R) and Ampligen(R) Against the Ebola Virus

GlobeNewswire November 3, 2014

Hemispherx Biopharma Reports New Evidence -- Based Potential of Ampligen(R) Against Ebola Virus Disease (EVD)

GlobeNewswire October 30, 2014

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola

GlobeNewswire October 20, 2014